Abstract
The recently introduced purine antimetabolite, 6-mercaptopurine, has been in clinical therapeutic trials in acute leukaemia at several centres in the last three years. The reports of such authors as Burchenal et al (1953), Hall et al (1954), Fountain (1955), and our own earlier experience (Hayhoe and Whitby 1955) have demonstrated that this substance is of potential value in three chief respects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Burchenal, J. H., M. L. Murphy, R. R. Ellison, M. P. Sykes, T. C. Tan, L. A. Leone, D. A. Karnofsky, L. F. Craver, H. W. Dargeon, and C. P. Rhoads: Clinical evaluation of a new antimetabolite, 6-mercaptopurine in the treatment of leukaemia and allied diseases. Blood 8, 965–999 (1953).
Fountain, J. R.: Treatment of leukaemia and allied disorders with 6-mercaptopurine. Brit. Med. J. 1, 1119 (1955).
Hall, B. H., M. D. Richards, F. M. Willet and T. V. Feichtmeir: Clinical experience with 6-mercaptopurine in human neoplasia. Ann. N. Y. Acad. Sci. 60, 374–384 (1954).
Hayhoe, F. G. J., and L. Whitby: The Management of Acute Leukaemia in Adults. Brit. J. Haematol. 1, 1–19 (1955).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1956 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hayhoe, F.G.J. (1956). The Treatment of Acute Leukaemia with 6-Mercaptopurine. In: Begemann, H. (eds) Fünfter Kongress der Europäischen Gesellschaft für Hämatologie, Freiburg i. Br., 20. bis 24. September 1955 / Cinquième Congrès de la Société Européenne d’Hématologie, Freiburg i. Br., Allemagne, 20–24 Septembre 1955. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-35395-0_22
Download citation
DOI: https://doi.org/10.1007/978-3-662-35395-0_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-02063-9
Online ISBN: 978-3-662-35395-0
eBook Packages: Springer Book Archive